Pituitary Hormone May Be Linked to Osteoporosis

If confirmed, finding could lead to new treatments to thwart bone loss, study says

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

By Amanda Gardner
HealthDay Reporter

THURSDAY, April 20, 2006 (HealthDay News) -- A hormone produced by the pituitary gland may play a role in bone loss in postmenopausal women, challenging the notion that declining estrogen levels are solely responsible for the problem.

High levels of the hormone, pituitary-derived follicle-stimulating hormone (FSH), caused an increase in bone loss in mice. And mice who lacked either the FSH hormone or its receptor became resistant to bone loss, even if they showed evidence of estrogen deficiency.

The findings open up the possibility that therapies other than estrogen to treat or prevent bone loss may one day be possible. Estrogen-replacement therapy is not an ideal solution because it has been linked to a heightened risk of breast cancer, especially when administered in combination with the hormone progestin.

"In essence, we're revisiting the pathophysiology of bone loss, attributing it not simply to loss of estrogen but to the accompanying elevation of FSH which occurs during menopause," said study author Dr. Mone Zaidi, a professor of medicine and physiology and director of the Mount Sinai Bone Program, at Mount Sinai School of Medicine in New York City. "The importance is that you could actually prevent bone loss without using a load of estrogen."

For now, however, the report, which appears in the April 21 issue of Cell, poses more questions than it answers.

"I personally think this is beautiful work and asks a lot of questions," said Dr. J. Christopher Gallagher, a professor of medicine and endocrinology at Creighton University School of Medicine in Omaha, Neb., and a board member of the North American Menopause Society. "But its true clinical importance is not yet clear."

Osteoporosis, a condition in which bones became more fragile and likely to break, affects nearly 45 million women globally, including 8 million in the United States. Healthy bones maintain a fine balance between formation and resorption -- or break-down. But after menopause, the bone break-down outpaces bone formation, resulting in bone loss.

So far, the broken balance has been attributed exclusively to loss of estrogen after menopause.

"It has really become virtually gospel that estrogen loss in women after menopause leads to bone loss," Zaidi said.

However, there were some holes in that theory. In some animal studies, taking away estrogen did not always result in bone loss, Zaidi said.

About two years ago, Zaidi's group discovered that thyroid-stimulating hormone, a sister hormone to FSH, affected bone remodeling.

Prior to menopause, FSH's role is to trigger egg development in women and to stimulate production of estrogen by the ovaries. As women get older, however, their estrogen levels decline. At that point, the pituitary gland attempts to restore estrogen levels by releasing more FSH.

"There's a feedback control between estrogen and FSH," Zaidi explained. "As estrogen falls, FSH rises."

In the new study, Zaidi and his colleagues showed that mice lacking FSH or its receptor did not experience bone loss, even if the ovaries were not producing estrogen.

Because this was an animal study, however, more research on humans is necessary.

"The next step would be to have a small molecule or antibody to mop up FSH in circulation and see if bone loss can be prevented," Zaidi said. "If that is the case, we have a new target" for prevention and treatment strategies.

Gallagher added: "It is an interesting clinical question because we've always ignored the height of FSH in postmenopausal women. We're going to need some prospective data, and I don't know of any studies currently looking at that. These are important questions."

More information

The National Osteoporosis Foundation has more on this disease.

SOURCES: Mone Zaidi, M.D., Ph.D., professor, medicine and physiology, and director, Mount Sinai Bone Program, Mount Sinai School of Medicine, New York City; J. Christopher Gallagher, M.D., professor, medicine and endocrinology, Creighton University School of Medicine, Omaha, Neb., and board member, North American Menopause Society; April 21, 2006, Cell

Last Updated: